Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Jazz Pharmaceuticals announced on March 5, 2025, an agreement to acquire Chimerix. Per deal terms, Chimerix investors will receive $8.55 a share, a 72% premium…
Jazz Pharmaceuticals is bolstering its oncology portfolio with the $935 million purchase of Chimerix and its experimental brain cancer drug dordaviprone.…
On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.) for adult and pediatric…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Jazz Pharmaceuticals acquired Chimerix for $8.55/share in cash, total equity value ~$935M, via a tender offer (expired April 17, 2025) followed by a merger that COMPLETED April 21, 2025, making Chimerix a wholly owned subsidiary. The deal's lead asset was dordaviprone, a first-in-class oral small molecule (ClpP agonist / DRD2 antagonist) for H3 K27M-mutant diffuse midline glioma, then under FDA Priority Review. The thesis delivered: on August 6, 2025 the FDA granted accelerated approval to dordaviprone as MODEYSO -- the first and only therapy for recurrent H3 K27M-mutant diffuse midline glioma (adult and pediatric >=1 yr, progressive disease after prior therapy), based on a pooled ORR of up to ~30% across five trials. The approval carried a Rare Pediatric Disease Priority Review Voucher (issued per Federal Register Aug 28, 2025), which Jazz sold for $200M (disclosed at JPM, January 2026) -- a material post-close value realization on top of the asset itself.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jazz Pharmaceuticals PLC / Chimerix, Inc. (this deal) | 2025 | $935M | — |
| Jazz Pharmaceuticals PLC / GW Pharmaceuticals | 2021 | $7.2B | 77 |
| Jazz Pharmaceuticals PLC / Celator Pharmaceuticals | 2016 | $1.5B | 73 |
| Jazz Pharmaceuticals PLC / AbCellera Biologics Inc. | 2026 | $848M | 50 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2025 deals · Jazz Pharmaceuticals PLC deals · Oncology deals